12:00 AM
 | 
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ditropan XL oxybutynin: Phase III; marketed

Data from a 226-patient Phase III trial showed an 81 percent reduction in urinary incontinence episodes (from 18.6 per week to 2.9 per week) with Ditropan XL versus a...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >